254 related articles for article (PubMed ID: 17965516)
1. Metabolism of tacrolimus (FK506) and recent topics in clinical pharmacokinetics.
Iwasaki K
Drug Metab Pharmacokinet; 2007 Oct; 22(5):328-35. PubMed ID: 17965516
[TBL] [Abstract][Full Text] [Related]
2. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II.
Staatz CE; Goodman LK; Tett SE
Clin Pharmacokinet; 2010 Apr; 49(4):207-21. PubMed ID: 20214406
[TBL] [Abstract][Full Text] [Related]
3. Tacrolimus concentrations in relation to CYP3A and ABCB1 polymorphisms among solid organ transplant recipients in Korea.
Jun KR; Lee W; Jang MS; Chun S; Song GW; Park KT; Lee SG; Han DJ; Kang C; Cho DY; Kim JQ; Min WK
Transplantation; 2009 Apr; 87(8):1225-31. PubMed ID: 19384171
[TBL] [Abstract][Full Text] [Related]
4. Combinational Effect of CYP3A5 and MDR-1 Polymorphisms on Tacrolimus Pharmacokinetics in Liver Transplant Patients.
Buendía JA; Otamendi E; Kravetz MC; Cairo F; Ruf A; de Davila M; Powazniak Y; Nafissi J; Lazarowski A; Bramuglia G; Villamil F
Exp Clin Transplant; 2015 Oct; 13(5):441-8. PubMed ID: 26450467
[TBL] [Abstract][Full Text] [Related]
5. CYP3A pharmacogenetics and tacrolimus disposition in adult heart transplant recipients.
Deininger KM; Vu A; Page RL; Ambardekar AV; Lindenfeld J; Aquilante CL
Clin Transplant; 2016 Sep; 30(9):1074-81. PubMed ID: 27314545
[TBL] [Abstract][Full Text] [Related]
6. Involvement of CYP 3A5 In the Interaction Between Tacrolimus and Nicardipine: A Case Report.
Sassi MB; Gaies E; Salouage I; Trabelsi S; Lakhal M; Klouz A
Curr Drug Saf; 2015; 10(3):254-6. PubMed ID: 25968921
[TBL] [Abstract][Full Text] [Related]
7. [Cytochrome P450 3A polymorphism and its importance in cyclosporine and tacrolimus therapy in transplanted patients].
Duricová J; Grundmann M
Ceska Slov Farm; 2007 Oct; 56(5):220-4. PubMed ID: 18064802
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenetic study of ABCB1 and CYP3A5 genes during the first year following heart transplantation regarding tacrolimus or cyclosporine levels.
Jordán de Luna C; Herrero Cervera MJ; Sánchez Lázaro I; Almenar Bonet L; Poveda Andrés JL; Aliño Pellicer SF
Transplant Proc; 2011; 43(6):2241-3. PubMed ID: 21839244
[TBL] [Abstract][Full Text] [Related]
9. Increased hospital stay and allograft dysfunction in renal transplant recipients with Cyp2c19 AA variant in SNP rs4244285.
Bosó V; Herrero MJ; Bea S; Galiana M; Marrero P; Marqués MR; Hernández J; Sánchez-Plumed J; Poveda JL; Aliño SF
Drug Metab Dispos; 2013 Feb; 41(2):480-7. PubMed ID: 23175667
[TBL] [Abstract][Full Text] [Related]
10. Polymorphism of the CYP3A5 gene and its effect on tacrolimus blood level.
Nair SS; Sarasamma S; Gracious N; George J; Anish TS; Radhakrishnan R
Exp Clin Transplant; 2015 Apr; 13 Suppl 1():197-200. PubMed ID: 25894154
[TBL] [Abstract][Full Text] [Related]
11. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus.
Hesselink DA; van Schaik RH; van der Heiden IP; van der Werf M; Gregoor PJ; Lindemans J; Weimar W; van Gelder T
Clin Pharmacol Ther; 2003 Sep; 74(3):245-54. PubMed ID: 12966368
[TBL] [Abstract][Full Text] [Related]
12. Effect of itraconazole on the concentrations of tacrolimus and cyclosporine in the blood of patients receiving allogeneic hematopoietic stem cell transplants.
Nara M; Takahashi N; Miura M; Niioka T; Kagaya H; Fujishima N; Saitoh H; Kameoka Y; Tagawa H; Hirokawa M; Sawada K
Eur J Clin Pharmacol; 2013 Jun; 69(6):1321-9. PubMed ID: 23354810
[TBL] [Abstract][Full Text] [Related]
13. ABCB1 genetic variant and its associated tacrolimus pharmacokinetics affect renal function in patients with rheumatoid arthritis.
Naito T; Mino Y; Aoki Y; Hirano K; Shimoyama K; Ogawa N; Kagawa Y; Kawakami J
Clin Chim Acta; 2015 May; 445():79-84. PubMed ID: 25817604
[TBL] [Abstract][Full Text] [Related]
14. Effects of genetic polymorphisms on the pharmacokinetics of calcineurin inhibitors.
Utecht KN; Hiles JJ; Kolesar J
Am J Health Syst Pharm; 2006 Dec; 63(23):2340-8. PubMed ID: 17106006
[TBL] [Abstract][Full Text] [Related]
15. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients.
Haufroid V; Mourad M; Van Kerckhove V; Wawrzyniak J; De Meyer M; Eddour DC; Malaise J; Lison D; Squifflet JP; Wallemacq P
Pharmacogenetics; 2004 Mar; 14(3):147-54. PubMed ID: 15167702
[TBL] [Abstract][Full Text] [Related]
16. Cytochrome P450 3A polymorphisms and immunosuppressive drugs: an update.
Anglicheau D; Legendre C; Beaune P; Thervet E
Pharmacogenomics; 2007 Jul; 8(7):835-49. PubMed ID: 18240909
[TBL] [Abstract][Full Text] [Related]
17. Cyp3A4, Cyp3A5, and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipients.
Roy JN; Barama A; Poirier C; Vinet B; Roger M
Pharmacogenet Genomics; 2006 Sep; 16(9):659-65. PubMed ID: 16906020
[TBL] [Abstract][Full Text] [Related]
18. Influence of CYP3A4, CYP3A5 and MDR-1 polymorphisms on tacrolimus pharmacokinetics and early renal dysfunction in liver transplant recipients.
Shi Y; Li Y; Tang J; Zhang J; Zou Y; Cai B; Wang L
Gene; 2013 Jan; 512(2):226-31. PubMed ID: 23107770
[TBL] [Abstract][Full Text] [Related]
19. Effects of voriconazole on tacrolimus metabolism in a kidney transplant recipient.
Capone D; Tarantino G; Gentile A; Sabbatini M; Polichetti G; Santangelo M; Nappi R; Ciotola A; D'Alessandro V; Renda A; Basile V; Federico S
J Clin Pharm Ther; 2010 Feb; 35(1):121-4. PubMed ID: 20175821
[TBL] [Abstract][Full Text] [Related]
20. Individualized Tacrolimus Therapy for Pediatric Nephrotic Syndrome: Considerations for Ontogeny and Pharmacogenetics of CYP3A.
Sun JY; Xu ZJ; Sun F; Guo HL; Ding XS; Chen F; Xu J
Curr Pharm Des; 2018; 24(24):2765-2773. PubMed ID: 30156148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
